Journal of Mid-life Health · 2021 · 11 citations · 20 references
MedicineEndocrinologyPharmacotherapyClinical PharmacologyReproductive EndocrinologyWomen's HealthHormonal InfluencesHormonal ManagementHormonal TherapyMenopause CareMenopause Hormone TherapyMenopause ManagementControl Group DesignEstradiol LevelsEstradiol TherapyHospital Stay DurationOpen-label TrialsOral Estrogen TherapyPostmenopausal Hormone TherapyStandard Of Care Comparators
Background: Protective role of estrogen in COVID-19 was speculated once the epidemiological studies reported increased susceptibility of estrogen-deficient population – males and postmenopausal females to severe disease category and involvement of angiotensin-converting enzyme 2 receptors and renin–angiotensin– aldosterone system in pathophysiology. Materials & Methods: An open-label randomized controlled trial was planned to assess the efficacy of short-course oral estradiol in preventing the clinical progression to severe disease and reduce case-fatality rate and the hospital stay duration in estrogen-deficient postmenopausal women. The intervention group ( n = 40) received 2 mg per day of estradiol valerate per orally for 7 days along with the standard care, while the control group ( n = 40) received only the standard care. Results: A significant difference was observed in the rate of reverse transcriptase–polymerase chain reaction negativization in the intervention versus control group at day 5 and day 7 of admission (42.5% vs. 15%, P = 0.007; 72.5% versus 50%, P = −0.026). No significant difference was noted in the duration of hospitalization ( P = 0.213). A significant decrease was noted in the mean values of inflammatory biomarkers – D-dimer, lactate dehydrogenase, and C-reactive protein on day 5 in the intervention group. Interleukin-6 also showed a declining trend on day 5 in the intervention group, while a rising trend was noted in the control arm. Only one case (2.5%) in the intervention group while seven in the control group (17.5%) progressed to the moderate category; however, the difference was not statistically significant ( P = 0.057). Conclusion Oral estradiol in postmenopausal females can be a novel and efficient option for managing nonsevere COVID-19 infection.
20
COVID-19: the gendered impacts of the outbreak
Clare Wenham, Julia Smith, Rosemary Morgan · The Lancet · 2020 · 1.8K citations · Full text
Veterinary Medicine, Emergency Preparedness, Infectious Diseases +17